# Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout

> **NCT01466166** · — · COMPLETED · sponsor: **Horizon Pharma Rheumatology LLC** · enrollment: 188 (actual)

## Conditions studied

- Refractory Chronic Gout

## Interventions

- **BIOLOGICAL:** Pegloticase

## Key facts

- **NCT ID:** NCT01466166
- **Lead sponsor:** Horizon Pharma Rheumatology LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-15
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-06-30
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01466166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01466166, "Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01466166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*